Efficient Targeting and Activation of Antigen-Presenting Cells In Vivo after Modified mRNA Vaccine Administration in Rhesus Macaques

Molecular Therapy

Volumn 25, Issue 12, 2017, Pages 2635-2647

  Liang, Frank ^a   Lindgren, Gustaf ^a   Lin, Ang ^a   Thompson, Elizabeth A ^a   Ols, Sebastian ^a   Röhss, Josefine ^a,b   John, Shinu ^b   Hassett, Kimberly ^b   Yuzhakov, Olga ^b   Bahl, Kapil ^b   Brito, Luis A ^b   Salter, Hugh ^a,b   Ciaramella, Giuseppe ^b   Loré, Karin ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b MODERNA THERAPEUTICS   (United States)

Author keywords

antigen presenting cells; mRNA vaccines; nonhuman primates

Indexed keywords

B7 ANTIGEN; CD86 ANTIGEN; LIPID NANOPARTICLE; MESSENGER RNA; NANOPARTICLE; RNA VACCINE; UNCLASSIFIED DRUG; VIRUS HEMAGGLUTININ; CYTOKINE; INFLUENZA VACCINE; VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL DIFFERENTIATION; CELL INFILTRATION; CONTROLLED STUDY; CXCL10 GENE; CYTOKINE PRODUCTION; DENDRITIC CELL; GENE; GENETIC ASSOCIATION; IMMUNIZATION; IMMUNOCOMPETENT CELL; IN VIVO STUDY; INHIBITION KINETICS; INNATE IMMUNITY; INTERNALIZATION; MONOCYTE; MX1 GENE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PHENOTYPE; RHESUS MONKEY; RNA TRANSLATION; UPREGULATION; ANIMAL; GENE EXPRESSION; GENETICS; IMMUNOLOGY; IMMUNOPHENOTYPING; INTRADERMAL DRUG ADMINISTRATION; LYMPH NODE; METABOLISM; T LYMPHOCYTE;

ANIMALS; ANTIGEN-PRESENTING CELLS; CYTOKINES; GENE EXPRESSION; IMMUNIZATION; IMMUNOPHENOTYPING; INFLUENZA VACCINES; INJECTIONS, INTRADERMAL; LYMPH NODES; MACACA MULATTA; PHENOTYPE; RNA, MESSENGER; T-LYMPHOCYTES; VACCINES;

EID: 85029684223     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1016/j.ymthe.2017.08.006     Document Type: Article

References (50)

1. Moingeon, P., Lombardi, V., Saint-Lu, N., Tourdot, S., Bodo, V., Mascarell, L., Adjuvants and vector systems for allergy vaccines. Immunol. Allergy Clin. North Am. 31 (2011), 407–419 xii.
2. Kranz, L.M., Diken, M., Haas, H., Kreiter, S., Loquai, C., Reuter, K.C., Meng, M., Fritz, D., Vascotto, F., Hefesha, H., et al. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature 534 (2016), 396–401.
3. Bogers, W.M., Oostermeijer, H., Mooij, P., Koopman, G., Verschoor, E.J., Davis, D., Ulmer, J.B., Brito, L.A., Cu, Y., Banerjee, K., et al. Potent immune responses in rhesus macaques induced by nonviral delivery of a self-amplifying RNA vaccine expressing HIV type 1 envelope with a cationic nanoemulsion. J. Infect. Dis. 211 (2015), 947–955.
4. Brito, L.A., Chan, M., Shaw, C.A., Hekele, A., Carsillo, T., Schaefer, M., Archer, J., Seubert, A., Otten, G.R., Beard, C.W., et al. A cationic nanoemulsion for the delivery of next-generation RNA vaccines. Mol. Ther. 22 (2014), 2118–2129.
5. Petsch, B., Schnee, M., Vogel, A.B., Lange, E., Hoffmann, B., Voss, D., Schlake, T., Thess, A., Kallen, K.J., Stitz, L., Kramps, T., Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection. Nat. Biotechnol. 30 (2012), 1210–1216.
6. Hekele, A., Bertholet, S., Archer, J., Gibson, D.G., Palladino, G., Brito, L.A., Otten, G.R., Brazzoli, M., Buccato, S., Bonci, A., et al. Rapidly produced SAM(®) vaccine against H7N9 influenza is immunogenic in mice. Emerg. Microbes Infect., 2, 2013, e52.
7. Pardi, N., Hogan, M.J., Pelc, R.S., Muramatsu, H., Andersen, H., DeMaso, C.R., Dowd, K.A., Sutherland, L.L., Scearce, R.M., Parks, R., et al. Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. Nature 543 (2017), 248–251.
8. Richner, J.M., Himansu, S., Dowd, K.A., Butler, S.L., Salazar, V., Fox, J.M., Julander, J.G., Tang, W.W., Shresta, S., Pierson, T.C., et al. Modified mRNA vaccines protect against Zika virus infection. Cell 168 (2017), 1114–1125.e10.
9. Anderson, B.R., Muramatsu, H., Jha, B.K., Silverman, R.H., Weissman, D., Karikó K., Nucleoside modifications in RNA limit activation of 2′-5′-oligoadenylate synthetase and increase resistance to cleavage by RNase L. Nucleic Acids Res. 39 (2011), 9329–9338.
10. Karikó K., Buckstein, M., Ni, H., Weissman, D., Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 23 (2005), 165–175.
11. Zangi, L., Lui, K.O., von Gise, A., Ma, Q., Ebina, W., Ptaszek, L.M., Später, D., Xu, H., Tabebordbar, M., Gorbatov, R., et al. Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction. Nat. Biotechnol. 31 (2013), 898–907.
12. Warren, L., Manos, P.D., Ahfeldt, T., Loh, Y.H., Li, H., Lau, F., Ebina, W., Mandal, P.K., Smith, Z.D., Meissner, A., et al. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell 7 (2010), 618–630.
13. Wang, Y., Su, H.H., Yang, Y., Hu, Y., Zhang, L., Blancafort, P., Huang, L., Systemic delivery of modified mRNA encoding herpes simplex virus 1 thymidine kinase for targeted cancer gene therapy. Mol. Ther. 21 (2013), 358–367.
14. Rettig, L., Haen, S.P., Bittermann, A.G., von Boehmer, L., Curioni, A., Krämer, S.D., Knuth, A., Pascolo, S., Particle size and activation threshold: a new dimension of danger signaling. Blood 115 (2010), 4533–4541.
15. Coelho, T., Adams, D., Silva, A., Lozeron, P., Hawkins, P.N., Mant, T., Perez, J., Chiesa, J., Warrington, S., Tranter, E., et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N. Engl. J. Med. 369 (2013), 819–829.
16. Bahl, K., Senn, J.J., Yuzhakov, O., Bulychev, A., Brito, L.A., Hassett, K.J., Laska, M.E., Smith, M., Almarsson, Ö., Thompson, J., et al. Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses. Mol. Ther. 25 (2017), 1316–1327.
17. Cox, R.J., Correlates of protection to influenza virus, where do we go from here?. Hum. Vaccin. Immunother. 9 (2013), 405–408.
18. Cros, J., Cagnard, N., Woollard, K., Patey, N., Zhang, S.Y., Senechal, B., Puel, A., Biswas, S.K., Moshous, D., Picard, C., et al. Human CD14dim monocytes patrol and sense nucleic acids and viruses via TLR7 and TLR8 receptors. Immunity 33 (2010), 375–386.
19. Lund, H., Boysen, P., Åkesson, C.P., Lewandowska-Sabat, A.M., Storset, A.K., Transient migration of large numbers of CD14(++) CD16(+) monocytes to the draining lymph node after onset of inflammation. Front. Immunol., 7, 2016, 322.
20. Loré K., Adams, W.C., Havenga, M.J., Precopio, M.L., Holterman, L., Goudsmit, J., Koup, R.A., Myeloid and plasmacytoid dendritic cells are susceptible to recombinant adenovirus vectors and stimulate polyfunctional memory T cell responses. J. Immunol. 179 (2007), 1721–1729.
21. + cells are a transient population of monocyte-derived macrophages. Immunity 41 (2014), 465–477.
22. Edwards, D.K., Jasny, E., Yoon, H., Horscroft, N., Schanen, B., Geter, T., Fotin-Mleczek, M., Petsch, B., Wittman, V., Adjuvant effects of a sequence-engineered mRNA vaccine: translational profiling demonstrates similar human and murine innate response. J. Transl. Med., 15, 2017, 1.
23. van den Elzen, P., Garg, S., León, L., Brigl, M., Leadbetter, E.A., Gumperz, J.E., Dascher, C.C., Cheng, T.Y., Sacks, F.M., Illarionov, P.A., et al. Apolipoprotein-mediated pathways of lipid antigen presentation. Nature 437 (2005), 906–910.
24. Chahal, J.S., Khan, O.F., Cooper, C.L., McPartlan, J.S., Tsosie, J.K., Tilley, L.D., Sidik, S.M., Lourido, S., Langer, R., Bavari, S., et al. Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single dose. Proc. Natl. Acad. Sci. USA 113 (2016), E4133–E4142.
25. Pollard, C., Rejman, J., De Haes, W., Verrier, B., Van Gulck, E., Naessens, T., De Smedt, S., Bogaert, P., Grooten, J., Vanham, G., et al. Type I IFN counteracts the induction of antigen-specific immune responses by lipid-based delivery of mRNA vaccines. Mol. Ther. 21 (2013), 251–259.
26. Montoya, M., Schiavoni, G., Mattei, F., Gresser, I., Belardelli, F., Borrow, P., Tough, D.F., Type I interferons produced by dendritic cells promote their phenotypic and functional activation. Blood 99 (2002), 3263–3271.
27. Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B.L., Tam, Y.K., Madden, T.D., Hope, M.J., Weissman, D., Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes. J. Control. Release 217 (2015), 345–351.
28. Kallen, K.J., Heidenreich, R., Schnee, M., Petsch, B., Schlake, T., Thess, A., Baumhof, P., Scheel, B., Koch, S.D., Fotin-Mleczek, M., A novel, disruptive vaccination technology: self-adjuvanted RNActive(®) vaccines. Hum. Vaccin. Immunother. 9 (2013), 2263–2276.
29. Oberli, M.A., Reichmuth, A.M., Dorkin, J.R., Mitchell, M.J., Fenton, O.S., Jaklenec, A., Anderson, D.G., Langer, R., Blankschtein, D., Lipid nanoparticle assisted mRNA delivery for potent cancer immunotherapy. Nano Lett. 17 (2017), 1326–1335.
30. Probst, J., Weide, B., Scheel, B., Pichler, B.J., Hoerr, I., Rammensee, H.G., Pascolo, S., Spontaneous cellular uptake of exogenous messenger RNA in vivo is nucleic acid-specific, saturable and ion dependent. Gene Ther. 14 (2007), 1175–1180.
31. De Sanctis, J.B., Blanca, I., Rivera, H., Bianco, N.E., Expression of low-density lipoprotein receptors in peripheral blood and tonsil B lymphocytes. Clin. Exp. Immunol. 113 (1998), 206–212.
32. Liang, F., Lindgren, G., Sandgren, K.J., Thompson, E.A., Francica, J.R., Seubert, A., De Gregorio, E., Barnett, S., O'Hagan, D.T., Sullivan, N.J., et al. Vaccine priming is restricted to draining lymph nodes and controlled by adjuvant-mediated antigen uptake. Sci. Transl. Med., 9, 2017, 9.
33. Liang, F., Ploquin, A., Hernández, J.D., Fausther-Bovendo, H., Lindgren, G., Stanley, D., Martinez, A.S., Brenchley, J.M., Koup, R.A., Loré K., Sullivan, N.J., Dissociation of skeletal muscle for flow cytometric characterization of immune cells in macaques. J. Immunol. Methods 425 (2015), 69–78.
34. Simmons, D.P., Wearsch, P.A., Canaday, D.H., Meyerson, H.J., Liu, Y.C., Wang, Y., Boom, W.H., Harding, C.V., Type I IFN drives a distinctive dendritic cell maturation phenotype that allows continued class II MHC synthesis and antigen processing. J. Immunol. 188 (2012), 3116–3126.
35. Kwissa, M., Nakaya, H.I., Onlamoon, N., Wrammert, J., Villinger, F., Perng, G.C., Yoksan, S., Pattanapanyasat, K., Chokephaibulkit, K., Ahmed, R., Pulendran, B., Dengue virus infection induces expansion of a CD14(+)CD16(+) monocyte population that stimulates plasmablast differentiation. Cell Host Microbe 16 (2014), 115–127.
36. Vono, M., Lin, A., Norrby-Teglund, A., Koup, R.A., Liang, F., Loré K., Neutrophils acquire the capacity for antigen presentation to memory CD4(+) T cells in vitro and ex vivo. Blood 129 (2017), 1991–2001.
37. Jongbloed, S.L., Kassianos, A.J., McDonald, K.J., Clark, G.J., Ju, X., Angel, C.E., Chen, C.J., Dunbar, P.R., Wadley, R.B., Jeet, V., et al. Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. J. Exp. Med. 207 (2010), 1247–1260.
38. Nestle, F.O., Di Meglio, P., Qin, J.Z., Nickoloff, B.J., Skin immune sentinels in health and disease. Nat. Rev. Immunol. 9 (2009), 679–691.
39. Gujer, C., Sundling, C., Seder, R.A., Karlsson Hedestam, G.B., Loré K., Human and rhesus plasmacytoid dendritic cell and B-cell responses to Toll-like receptor stimulation. Immunology 134 (2011), 257–269.
40. Francica, J.R., Sheng, Z., Zhang, Z., Nishimura, Y., Shingai, M., Ramesh, A., Keele, B.F., Schmidt, S.D., Flynn, B.J., Darko, S., et al., NISC Comparative Sequencing Program. Analysis of immunoglobulin transcripts and hypermutation following SHIV(AD8) infection and protein-plus-adjuvant immunization. Nat. Commun., 6, 2015, 6565.
41. Halliley, J.L., Tipton, C.M., Liesveld, J., Rosenberg, A.F., Darce, J., Gregoretti, I.V., Popova, L., Kaminiski, D., Fucile, C.F., Albizua, I., et al. Long-lived plasma cells are contained within the CD19(-)CD38(hi)CD138(+) subset in human bone marrow. Immunity 43 (2015), 132–145.
42. Broos, K., Van der Jeught, K., Puttemans, J., Goyvaerts, C., Heirman, C., Dewitte, H., et al. Particle-mediated intravenous delivery of antigen mRNA results in strong antigen-specific T-cell responses despite the induction of type I interferon. Mol. Ther. Nucleic Acids, 5, 2016, e326.
43. De Beuckelaer, A., Pollard, C., Van Lint, S., Roose, K., Van Hoecke, L., Naessens, T., Udhayakumar, V.K., Smet, M., Sanders, N., Lienenklaus, S., et al. Type I interferons interfere with the capacity of mRNA lipoplex vaccines to elicit cytolytic T cell responses. Mol. Ther. 24 (2016), 2012–2020.
44. Kastenmüller, K., Wille-Reece, U., Lindsay, R.W., Trager, L.R., Darrah, P.A., Flynn, B.J., Becker, M.R., Udey, M.C., Clausen, B.E., Igyarto, B.Z., et al. Protective T cell immunity in mice following protein-TLR7/8 agonist-conjugate immunization requires aggregation, type I IFN, and multiple DC subsets. J. Clin. Invest. 121 (2011), 1782–1796.
45. Welsh, R.M., Bahl, K., Marshall, H.D., Urban, S.L., Type 1 interferons and antiviral CD8 T-cell responses. PLoS Pathog., 8, 2012, e1002352.
46. Bui, H.H., Peters, B., Assarsson, E., Mbawuike, I., Sette, A., Ab and T cell epitopes of influenza A virus, knowledge and opportunities. Proc. Natl. Acad. Sci. USA 104 (2007), 246–251.
47. Athale, S., Banchereau, R., Thompson-Snipes, L., Wang, Y., Palucka, K., Pascual, V., Banchereau, J., Influenza vaccines differentially regulate the interferon response in human dendritic cell subsets. Sci. Transl. Med., 9, 2017, 9.
48. Tewari, K., Flynn, B.J., Boscardin, S.B., Kastenmueller, K., Salazar, A.M., Anderson, C.A., Soundarapandian, V., Ahumada, A., Keler, T., Hoffman, S.L., et al. Poly(I:C) is an effective adjuvant for antibody and multi-functional CD4+ T cell responses to Plasmodium falciparum circumsporozoite protein (CSP) and αDEC-CSP in non human primates. Vaccine 28 (2010), 7256–7266.
49. Coffman, R.L., Sher, A., Seder, R.A., Vaccine adjuvants: putting innate immunity to work. Immunity 33 (2010), 492–503.
50. Trumpfheller, C., Caskey, M., Nchinda, G., Longhi, M.P., Mizenina, O., Huang, Y., Schlesinger, S.J., Colonna, M., Steinman, R.M., The microbial mimic poly IC induces durable and protective CD4+ T cell immunity together with a dendritic cell targeted vaccine. Proc. Natl. Acad. Sci. USA 105 (2008), 2574–2579.